Patient-reported outcomes are important predictors of morbidity and mortality. The validity and reliability of the Patient Reported Outcomes Measurement Information System (PROMIS) computerized adaptive tests (CATs) has been assessed in patients with systemic lupus erythematosus, but does PROMIS deliver on its promise?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kasturi, S. et al. Validity and reliability of Patient Reported Outcomes Measurement Information System computerized adaptive tests in systemic lupus erythematosus. J. Rheumatol. http://dx.doi.org/10.3899/jrheum.161202 (2017).
Jolly, M. et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin. Arthritis Rheum. 42, 56–65 (2012).
McElhone, K. et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 57, 972–979 (2007).
Katz, P., Pedro, S. & Michaud, K. Performance of the PROMIS 29-item profile in rheumatoid arthritis, osteoarthritis, fibromyalgia, and systemic lupus erythematosus. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.23183 (2016).
Ow, Y. L. et al. Domains of health-related quality of life important and relevant to multiethnic English-speaking Asian systemic lupus erythematosus patients: a focus group study. Arthritis Care Res. (Hoboken) 63, 899–908 (2011).
Jolly, M. & Utset, T. O. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 13, 924–926 (2004).
Jolly, M., Kosinski, M., Garris, C. P. & Oglesby, A. K. Prospective validation of the lupus impact tracker: a patient-completed tool for clinical practice to evaluate the impact of systemic lupus erythematosus. Arthritis Rheumatol. 68, 1422–1431 (2016).
US Food and Drug Administration. Guidance for industry — patient-reported outcome measures: use in medical product development to support labeling claims. FDA https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm119328.pdf (2009).
Giangreco, D., Devilliers, H., Annapureddy, N., Block, J. A. & Jolly, M. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus. Lupus 24, 1486–1491 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.J. declares that she is the inventor of LupusPRO and Lupus Impact Tracker, the copyrights for which are owned by Rush University Medical Center and the University of Illinois at Chicago, Illinois, USA. P.K. declares no competing interests.
Rights and permissions
About this article
Cite this article
Jolly, M., Katz, P. The promise of PROMIS — is it ready for prime time in SLE?. Nat Rev Rheumatol 13, 453–454 (2017). https://doi.org/10.1038/nrrheum.2017.100
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.100
